Our findings shed light on the mechanism between CDCC69 and tumor-immune interactions, posing that CDCC69 could serve as a novel and potential biomarker to predict BC prognosis and sensitivity to PD-1/PD-L1 inhibitor therapy. This evidence concerns the gene CD274 and neoplasm.